en
svPress releases
Regulatory press release 2023-10-24
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2024
Press release 2023-09-15
Xspray Pharma appoints Chief Commercial Officer to drive upcoming Dasynoc™ US product commercialization
Regulatory press release 2023-09-11
Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc™ Patent Litigation, Paving Way for Early Market Launch
Regulatory press release 2023-08-02
Interim Report Second Quarter 2023
Regulatory press release 2023-07-31
New number of shares and votes in Xspray Pharma
Regulatory press release 2023-07-11
Xspray Pharma receives request for additional information concerning Dasynoc from FDA
Regulatory press release 2023-06-27
Xspray raises approximately SEK 251 million through a rights issue
Regulatory press release 2023-05-30
Xspray has published prospectus relating to its previously announced rights issue
Regulatory press release 2023-05-30
The Board of Directors of Xspray has resolved on a previously announced rights issue of units of approximately SEK 300 million ahead of Dasynoc product launch
Regulatory press release 2023-05-25